The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

Minimally-invasive techniques such as stenting have been widely adopted in Brazil. The coronary stents market will be driven by the rising prevalence of CAD, the growing aging population, and the potential cost savings associated with DES technologies.

Scope

• An overview of Coronary Stents, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized the SA Coronary Stents market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
• Investigation of current and future market competition for Coronary Stents.
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Coronary Stents sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

• Understand the trends shaping and driving the SA Coronary Stents market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in the SA Coronary Stents market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in the SA Coronary Stents market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 8
1.1 List of Tables 16
1.2 List of Figures 23

2 Introduction 25
2.1 Catalyst 26
2.2 Related Reports 27

3 Industry Overview 28
3.1 Disease Overview 28
3.2 Clinical Outcomes 29
3.2.1 Treatment Guidelines 29
3.2.2 Treatment Modalities 30
3.3 Procedure Trends 44
3.3.1 Brazil 46
3.4 Market Access 47
3.4.1 Regulatory Process 48
3.4.2 Physician Decision-Making Process 49
3.4.3 Role of Group Purchasing Organizations 53
3.4.4 Lack of Clinical Data 56
3.4.5 Regional-Level Control 58
3.4.6 Cost Considerations 59
3.4.7 Reimbursement Trends 60
3.5 Regulatory Issues/Recalls 61
3.5.1 Regulatory Issues 61
3.5.2 Product Recalls 61
3.6 Mergers and Acquisitions/ Key Partnerships 62
3.6.1 Medtronic and Covidien 62
3.6.2 Arterial Remodeling Technologies and Terumo Corporation 62
3.6.3 MicroPort Scientific Corporation and Cordis Corporation 63
3.6.4 Alvimedica and CID 63
3.6.5 ITGI Medical and Vascular Solutions 64
3.6.6 Terumo Corporation and Onset Medical Corporation 64
3.6.7 Atrium Medical and Getinge Group 64
3.6.8 C.R. Bard and ClearStream Technologies 65
3.6.9 Biosensors International and Devax, CardioMind, and JW Medical Systems 65
3.6.10 CeloNova Biosciences and Nexeon MedSystems 66
3.6.11 Medtronic and Invatec 67
3.6.12 Micell Technologies and Maxcor Lifescience 67
3.6.13 Boston Scientific Corporation and Guidant Corporation 68
3.6.14 Abbott Vascular and Guidant Corporation 68
3.6.15 Kaneka Corporation and Fujisawa Pharmaceuticals 68
3.7 Economic Impact of Coronary Artery Disease 69
3.7.1 Brazil 70
3.8 Treatment Costs for Coronary Artery Disease 70

4 Unmet Needs 72
4.1 Need for Better Clinical Outcomes in Specific Lesions 72
4.1.1 Chronic Total Occlusions 72
4.1.2 Small-Vessel Coronary Lesions 73
4.1.3 Heavily-Calcified and Uncrossable/Undilatable Lesions 74
4.1.4 Bifurcation Lesions 74
4.1.5 Saphenous Vein Graft Intervention 75
4.2 Eliminating Mechanisms of Failure With Balloon Angioplasty 76
4.3 Late Myocardial Infarction After Stenting 76
4.4 Eliminating the Permanent Polymer 77
4.5 In-Stent Restenosis 78
4.6 Stent-In-Stent Procedures 80
4.7 Prolonged Dual Antiplatelet Therapy 81
4.8 Lack of Homogenous Drug Distribution 82
4.9 Delayed Stent Endothelialization 82
4.10 Negative Vessel Remodeling 83
4.11 Need for Effective Therapy for Specific Patient Populations 83
4.12 Addressing the Complications of Coronary Artery Bypass Grafting 84

5 Market Opportunity Analysis 85
5.1 Improve Stent Design/Platform 85
5.1.1 Stent Coating Technology 86
5.1.2 Bioabsorbable Stent Technology 88
5.1.3 Antiproliferative Drug and Elution Kinetics 89
5.2 Hybrid Stent Systems 91
5.3 Effective Therapies for Challenging Coronary Indications 92
5.3.1 Chronic Total Occlusions 92
5.3.2 Small-Vessel Disease 92
5.3.3 Bifurcation Lesions 93
5.3.4 Diffuse Atherosclerotic Disease 94
5.3.5 Saphenous Vein Graft Intervention 94
5.3.6 Acute Myocardial Infarction 94
5.4 Target Challenging Patient Populations 95
5.5 Emerging Markets 96

6 Market Drivers, Barriers, and Substitutes 97
6.1 Market Drivers 97
6.1.1 Rising Prevalence of Disease 98
6.1.2 Viable Treatment for Challenging Coronary Indications 99
6.1.3 Innovations in Stent Technology 100
6.1.4 Development of Bioabsorbable Stents 102
6.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 104
6.1.6 Potential Cost Savings 105
6.1.7 Use of Imaging Modalities for Accurate Stent Placement 106
6.1.8 Adoption of Stents in the Emerging Markets 106
6.1.9 Launch of Bioabsorbable Stents in US and Japan 107
6.2 Market Barriers 107
6.2.1 Concerns Regarding Overstenting 107
6.2.2 Post-ProceduraI Complications of Drug-Eluting Stenting 108
6.2.3 Risk of Perioperative Adverse Cardiac Events Post-Stenting 108
6.2.4 Slow Adoption of Bioabsorbable Stents 109
6.2.5 Lack of Reimbursement 114
6.2.6 Healthcare Cost-Cutting and Reimbursement 115
6.2.7 Availability of Venture Capital 116
6.2.8 Medical Device Excise Tax 117
6.3 Market Substitutes 117
6.3.1 Drug-Eluting Balloons 117
6.3.2 Liquid Drug Delivery Catheter 119

7 Competitive Assessment 121
7.1 Overview 121
7.2 Trends in Coronary Stent Technology Development 122
7.2.1 Development of Bare Metal Stents 122
7.2.2 Development of Drug-Eluting Stents 124
7.2.3 Development of Bioabsorbable Stents 127
7.2.4 Development of Covered Stents 128
7.2.5 Coronary Stent Technology SWOT Analysis 129
7.3 Global Company Market Share 130
7.3.1 Bare Metal Stent Market Share 130
7.3.2 Drug-Eluting Stent Market Share 131
7.4 Regional Company Market Share 132
7.4.1 Brazil Market Share 132

8 Pipeline Products 135
8.1 Overview 135
8.2 Pipeline by Stage of Development 135
8.3 Pipeline Product Profiles 138
8.3.1 Bioabsorbable Stents 138
8.3.2 Other Types of Vascular Stents 149

9 Clinical Trial Analysis 155
9.1 Overview 155
9.2 Clinical Trials to Watch 155
9.2.1 Evaluating the Latest and New Generation of Drug-Eluting Stents 155
9.2.2 Bioabsorbable Stent Clinical Trials 157
9.2.3 Evaluating Stenting in Challenging Coronary Indications/Patient Populations 161
9.2.4 Targeting Patient Populations in the APAC Region 163

10 Current and Future Players 165
10.1 Overview 165
10.2 Trends in Corporate Strategy 165
10.3 Company Profiles 168
10.3.1 Abbott Vascular 168
10.3.2 Boston Scientific Corporation 174
10.3.3 Medtronic 181
10.3.4 Alvimedica 187
10.3.5 Amaranth Medical 191
10.3.6 amg International 194
10.3.7 Arterial Remodeling Technologies 198
10.3.8 B. Braun 201
10.3.9 Balton 204
10.3.10 Biosensors International 209
10.3.11 Biotronik 213
10.3.12 Blue Medical 218
10.3.13 Cardionovum 222
10.3.14 C.R. Bard 226
10.3.15 Elixir Medical Corporation 230
10.3.16 eucatech AG 235
10.3.17 Hexacath 239
10.3.18 IRAMED 242
10.3.19 JW Medical Systems 245
10.3.20 Kyoto Medical Planning 248
10.3.21 Lepu Medical Technology 251
10.3.22 MicroPort Scientific Corporation 255
10.3.23 Minvasys 259
10.3.24 MIV Therapeutics 263
10.3.25 Opto Circuits 267
10.3.26 OrbusNeich Medical 271
10.3.27 Relisys Medical Devices 275
10.3.28 REVA Medical 279
10.3.29 Sahajanand Medical Technologies 282
10.3.30 STENTYS 286
10.3.31 Terumo Corporation 290
10.3.32 Translumina 294
10.3.33 Vascular Concepts 298
10.3.34 Other Companies 302

11 Market Outlook 314
11.1 By Market Segment 314
11.1.1 Overview 314
11.1.2 Drug-Eluting Stent Market 315
11.1.3 Bare Metal Stent Market 317
11.1.4 Emerging Stent Technologies 318
11.2 By Indication 320
11.3 By Geography 321
11.3.1 Brazil 321

12 Appendix 324
12.1 Bibliography 324
12.2 Abbreviations 348
12.3 Report Methodology 355
12.3.1 Overview 355
12.3.2 Coverage 355
12.3.3 Secondary Research 355
12.4 Physicians and Specialists Included in This Study 357
12.4.1 Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI 357
12.4.2 Bernado Cortese, MD, FESC 357
12.4.3 Ricardo A. Costa, MD 357
12.4.4 Thomas Cuisset, MD, PhD, FESC 357
12.4.5 Nobuyuki Komiyama, MD, PhD, FACC, FJCC 357
12.4.6 Roger J. Laham, MD 357
12.4.7 Mark W. Mewissen, MD 357
12.4.8 Gary S. Mintz, MD 357
12.4.9 Tudor C. Poerner, MD 358
12.4.10 David Ramsdale, MD, PhD 358
12.4.11 Gregory A. Sgueglia, MD, PhD 358
12.4.12 Madhukar Shahi, MD 358
12.4.13 Takehiro Yamashita, MD, PhD, FACC 358
12.5 Primary Research 359
12.5.1 Primary Research - Key Opinion Leader Interviews 359
12.5.2 Primary Research Interviews- Physician and Industry Participants 360
12.5.3 Physican Survey 361
12.5.4 Expert Panel Validation 361
12.6 Forecasting Methodology 362
12.7 About the Authors 364
12.7.1 Analysts 364
12.7.2 Global Head of Healthcare 365
12.8 About MediPoint 366
12.9 About GlobalData 366
12.10 Disclaimer 366

List of Tables

Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD* 30
Table 2: Types of CABG 33
Table 3: Complications of CABG 34
Table 4: Drugs Incorporated Into DES 37
Table 5: Types of Lesions Treated Using Atherectomy 41
Table 6: GPOs in the US and EU 54
Table 7: Direct and Indirect Healthcare Costs of CAD 69
Table 8: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020 71
Table 9: Coronary Stent Technology SWOT Analysis, 2014 129
Table 10: Global Coronary Stent Pipeline Products, 2014 137
Table 11: ART18Z SWOT Analysis, 2014 139
Table 12: DREAMS SWOT Analysis, 2014 140
Table 13: Fantom SWOT Analysis, 2014 141
Table 14: Fortitude SWOT Analysis, 2014 142
Table 15: Ideal BioStent SWOT Analysis, 2014 143
Table 16: Igaki-Tamai Stent SWOT Analysis, 2014 145
Table 17: ON-AVS SWOT Analysis, 2014 146
Table 18: Other Companies Developing BAS, 2014 149
Table 19: FOCUS np Eluting Stent SWOT Analysis, 2014 150
Table 20: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014 151
Table 21: Svelte Drug-Eluting Stent SWOT Analysis, 2014 153
Table 22: Clinical Trials Evaluating the Latest and New Generation of DES, 2014 156
Table 23: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014 162
Table 24: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014 164
Table 25: Abbott Vascular Company Profile 168
Table 26: Abbott Vascular Coronary Stent Marketed Products 170
Table 27: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014 173
Table 28: Abbott Vascular SWOT Analysis, 2014 174
Table 29: Boston Scientific Corporation Company Profile 175
Table 30: Boston Scientific Coronary Stent Marketed Products 177
Table 31: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014 180
Table 32: Boston Scientific Corporation SWOT Analysis, 2014 181
Table 33: Medtronic Company Profile 182
Table 34: Medtronic Coronary Stent Marketed Products 184
Table 35: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014 186
Table 36: Medtronic SWOT Analysis, 2014 187
Table 37: Alvimedica Company Profile 188
Table 38: Alvimedica Coronary Stent Marketed Products 189
Table 39: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014 190
Table 40: Alvimedica SWOT Analysis, 2014 191
Table 41: Amaranth Medical Company Profile 192
Table 42: Amaranth Medical Coronary Stent Pipeline Product 192
Table 43: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 193
Table 44: Amaranth Medical SWOT Analysis, 2014 193
Table 45: amg International Company Profile 194
Table 46: amg International Coronary Stent Marketed Products 196
Table 47: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014 197
Table 48: amg International SWOT Analysis, 2014 198
Table 49: Arterial Remodeling Technologies Company Profile 199
Table 50: Arterial Remodeling Technologies Coronary Stent Pipeline Product 199
Table 51: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 200
Table 52: Arterial Remodeling Technologies SWOT Analysis, 2014 200
Table 53: B. Braun Company Profile 201
Table 54: B. Braun Coronary Stent Marketed Products 202
Table 55: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014 203
Table 56: B. Braun SWOT Analysis, 2014 204
Table 57: Balton Company Profile 205
Table 58: Balton Coronary Stent Marketed Products 206
Table 59: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014 208
Table 60: Balton SWOT Analysis, 2014 208
Table 61: Biosensors International Company Profile 209
Table 62: Biosensors International Coronary Stent Marketed Products 211
Table 63: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014 212
Table 64: Biosensors International SWOT Analysis, 2014 213
Table 65: Biotronik Company Profile 214
Table 66: Biotronik Coronary Stent Marketed and Pipeline Products 215
Table 67: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014 217
Table 68: Biotronik SWOT Analysis, 2014 218
Table 69: Blue Medical Company Profile 219
Table 70: Blue Medical Coronary Stent Marketed Products 220
Table 71: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 221
Table 72: Blue Medical SWOT Analysis, 2014 222
Table 73: Cardionovum Company Profile 223
Table 74: Cardionovum Coronary Stent Marketed and Pipeline Products 224
Table 75: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014 225
Table 76: Cardionovum SWOT Analysis, 2014 226
Table 77: C.R. Bard Company Profile 227
Table 78: ClearStream Technologies Coronary Stent Marketed Products 228
Table 79: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014 229
Table 80: C.R. Bard SWOT Analysis, 2014 230
Table 81: Elixir Medical Corporation Company Profile 231
Table 82: Elixir Medical Corporation Coronary Stent Marketed Products 232
Table 83: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 234
Table 84: Elixir Medical Corporation SWOT Analysis, 2014 235
Table 85: eucatech Profile 236
Table 86: eucatech Coronary Stent Marketed Products 237
Table 87: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014 238
Table 88: eucatech SWOT Analysis, 2014 239
Table 89: Hexacath Company Profile 240
Table 90: Hexacath Coronary Stent Marketed Products 241
Table 91: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014 241
Table 92: Hexacath SWOT Analysis, 2014 242
Table 93: IRAMED Company Profile 242
Table 94: IRAMED Coronary Stent Marketed Products 243
Table 95: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014 244
Table 96: IRAMED SWOT Analysis, 2014 245
Table 97: JW Medical Systems Company Profile 246
Table 98: JW Medical Systems Coronary Stent Marketed Product 246
Table 99: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014 247
Table 100: JW Medical Systems SWOT Analysis, 2014 248
Table 101: Kyoto Medical Planning Company Profile 249
Table 102: Kyoto Medical Planning Coronary Stent Pipeline Product 250
Table 103: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014 250
Table 104: Kyoto Medical Planning SWOT Analysis, 2014 251
Table 105: Lepu Medical Technology Company Profile 252
Table 106: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products 253
Table 107: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014 254
Table 108: Lepu Medical Technology SWOT Analysis, 2014 255
Table 109: MicroPort Scientific Corporation Company Profile 256
Table 110: MicroPort Scientific Corporation Coronary Stent Marketed Products 257
Table 111: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 258
Table 112: MicroPort Scientific Corporation SWOT Analysis, 2014 259
Table 113: Minvasys Company Profile 260
Table 114: Minvasys Coronary Stent Marketed and Pipeline Products 261
Table 115: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014 262
Table 116: Minvasys SWOT Analysis, 2014 263
Table 117: MIV Therapeutics Company Profile 264
Table 118: MIV Therapeutics Coronary Stent Marketed Products 265
Table 119: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014 266
Table 120: MIV Therapeutics SWOT Analysis, 2014 267
Table 121: Opto Circuits Company Profile 268
Table 122: Opto Circuits Coronary Stent Marketed Products 269
Table 123: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014 270
Table 124: Opto Circuits SWOT Analysis, 2014 271
Table 125: OrbusNeich Medical Company Profile 272
Table 126: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products 273
Table 127: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 274
Table 128: OrbusNeich Medical SWOT Analysis, 2014 275
Table 129: Relisys Medical Devices Company Profile 276
Table 130: Relisys Medical Devices Coronary Stent Marketed Products 277
Table 131: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014 278
Table 132: Relisys Medical Devices SWOT Analysis, 2014 279
Table 133: REVA Medical Company Profile 280
Table 134: REVA Medical Coronary Stent Pipeline Product 280
Table 135: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 281
Table 136: REVA Medical SWOT Analysis, 2014 282
Table 137: Sahajanand Medical Technologies Company Profile 283
Table 138: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products 284
Table 139: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 285
Table 140: Sahajanand Medical Technologies SWOT Analysis, 2014 286
Table 141: STENTYS Company Profile 287
Table 142: STENTYS Coronary Stent Marketed and Pipeline Products 288
Table 143: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014 289
Table 144: STENTYS SWOT Analysis, 2014 290
Table 145: Terumo Corporation Company Profile 291
Table 146: Terumo Corporation Coronary Stent Marketed and Pipeline Products 292
Table 147: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 293
Table 148: Terumo Corporation SWOT Analysis, 2014 294
Table 149: Translumina Company Profile 295
Table 150: Translumina Coronary Stent Marketed Products 296
Table 151: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014 297
Table 152: Translumina SWOT Analysis, 2014 297
Table 153: Vascular Concepts Company Profile 298
Table 154: Vascular Concepts Coronary Stent Marketed Products 299
Table 155: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014 300
Table 156: Vascular Concepts SWOT Analysis, 2014 301
Table 157: Other Companies in the Coronary Stent Market, North America, 2014 302
Table 158: Other Companies in the Coronary Stent Market, EU, 2014 307
Table 159: Other Companies in the Coronary Stent Market, APAC, 2014 310
Table 160: Other Companies in the Coronary Stent Market, South Africa and South America, 2014 313
Table 161: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 314
Table 162: Global DES Sales ($m) Forecast, 2011-2020 315
Table 163: Global BMS Sales ($m) Forecast, 2011-2020 317
Table 164: Coronary Stents Market Sales ($m) Forecast for Brazil, 2011-2020 322
Table 165: Primary Research Interviews Completed 360
Table 166: Physicians Surveyed, By Country 361

List of Figures

Figure 1: Pathophysiology of CAD 28
Figure 2: CAD Treatment Modalities 31
Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58) 32
Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58) 35
Figure 5: Types of Stents Used to Treat CAD 36
Figure 6: Example of a BMS 37
Figure 7: Example of a DEB 40
Figure 8: Types of Atherectomy 42
Figure 9: Global Coronary Stenting Procedure Volume, 2011-2020 45
Figure 10: Brazil Coronary Stenting Procedure Volume, 2011-2020 47
Figure 11: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020 71
Figure 12: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58) 79
Figure 13: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58) 81
Figure 14: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101) 86
Figure 15: Global Coronary Stents Market Value Share (%), 2013 and 2020 122
Figure 16: Global BMS Company Market Share (%), 2013 131
Figure 17: Global DES Company Market Share (%), 2013 132
Figure 18: Brazil Market Share for BMS (%), 2013 133
Figure 19: Brazil Market Share for DES (%), 2013 134
Figure 20: Global Coronary Stent Pipeline Products by Stage of Development, 2014 136
Figure 21: Global Coronary Stents Market Revenue ($m), 2011-2020 315
Figure 22: Global DES Market Revenue ($m), 2011-2020 316
Figure 23: Global BMS Market Revenue ($m), 2011-2020 318
Figure 24: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101) 320
Figure 25: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101) 321
Figure 26: Brazilian Sales ($m) Forecast for Coronary Stents, 2011-2020 322